Table 3. Anti-tumour efficacy of SCOUT.
| Outcome, n (%) | Patients at all doses (n=45) | MTD patients (n=29) |
|---|---|---|
| Not assessablea | 7 | 4 |
| Evaluable patients | 38 | 25 |
| Complete response, n (%)b | 0 | 0 |
| Partial response, n (%)b | 24 (63) | 17 (68) |
| Stable disease, n (%)b | 10 (26) | 8 (32) |
| Disease control rate (95% CI)c | 89 (75–97) | 100 (86–100) |
| Progressive disease, n (%)b | 4 (11) | 0 |
| Objective response rate (95% CI) | 63 (46–78) | 68 (46–85) |
CI=confidence interval; MTD=maximum tolerated dose.
a
Patients did not receive two treatment cycles and were thus not assessable for response.
b
Based on the number of evaluable patients.
c
Complete response+partial response+stable disease rates.